1. Scrip
  2. >>Therapy Areas

Janssen touches BACE with Shionogi for early-stage Alzheimer's candidates

 
• By Ian Haydock

Janssen Pharmaceuticals has acquired rights to a series of oral inhibitors of the beta-site amyloid precursor protein-cleaving enzyme (BACE) in preclinical development for Alzheimer's disease at the Japanese firm Shionogi.

Janssen Pharmaceuticals has acquired rights to a series of oral inhibitors of the beta-site amyloid precursor protein-cleaving enzyme (BACE) in preclinical development for Alzheimer's disease at the Japanese firm Shionogi.

The license and collaboration agreement will see the Johnson & Johnson business unit carry out clinical development work through its Janssen Research and Development affiliate, with Shionogi to receive an undisclosed

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

More from Therapeutic Category

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 
• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.